{"id":4749,"date":"2026-08-27T11:07:03","date_gmt":"2026-08-27T09:07:03","guid":{"rendered":"https:\/\/mumak.me\/?p=4749"},"modified":"2026-09-15T16:55:49","modified_gmt":"2026-09-15T14:55:49","slug":"valuation-analysis-revolution-medicines","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/research-insights\/valuation-analysis\/valuation-analysis-revolution-medicines\/","title":{"rendered":"Valuation Analysis: Revolution Medicines"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\"\"\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t

Revolution Medicines<\/h4>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tAnalysis result: 5 out of 5 MUMAKS\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Rating<\/h2>

This analysis evaluates Revolution Medicines according to the MUMAK UMBRELLA strategy. <\/span><\/p>

The valuation is conducted across five decision-making phases: Geopolitics<\/strong>, Industry<\/strong>, Fundamentals<\/strong>, Market Sentiment<\/strong>, and Technical Analysis.<\/strong><\/span><\/p>

The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic. <\/span> <\/span><\/p>

We explain \u2013 you decide.<\/span><\/b> <\/span><\/p>

Revolution Medicines has achieved a crucial milestone with Daraxonrasib. The U.S. Food and Drug Administration approved the drug on August 26, 2026, under the brand name RASONQUE<\/strong> for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not suitable for multi-agent systemic therapy. <\/p>

The Phase 3 study RASolute 302<\/strong> forms the clinical basis of the approval. Daraxonrasib increased median overall survival to 13.2 months compared to 6.7 months<\/strong> with chemotherapy. The risk of death was reduced by 60%<\/strong>. Progression-free survival also improved to 7.2 months compared to 3.6 months. <\/p>

Particularly relevant for the commercial perspective is the comparatively broad label: The approval applies with or without an identified RAS mutation and does not require a companion diagnostic test<\/strong>.<\/p>

This significantly shifts the investment case. The central question is no longer whether Daraxonrasib will achieve the first FDA approval, but whether Revolution Medicines can develop a multi-billion dollar RAS oncology platform<\/strong> from it. <\/p>

Geopolitics<\/h3>

Classification <\/strong><\/h4>

For Revolution Medicines, the regulatory and health policy environment is more crucial than classical geopolitics.<\/p>

Here, the initial situation has fundamentally improved.<\/p>

The FDA granted full approval for RASONQUE on August 26, 2026<\/strong>. The drug is already prescribable in the USA. The approval occurred within an exceptionally accelerated regulatory process and was supported by Breakthrough Therapy Designation, Orphan Drug Designation, and the Commissioner\u2019s National Priority Voucher. <\/p>

The regulatory process is also progressing internationally. The European Medicines Agency already initiated a rolling review of Daraxonrasib<\/strong> in July to accelerate the assessment of the marketing authorization application. <\/p>

This eliminates the largest single regulatory risk of the investment case to date.<\/p>

The new risks now lie more with reimbursement, price acceptance, and international approval<\/strong>.<\/p>

Opportunities<\/h5>